Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-003 in Healthy Volunteers and Ulcerative Colitis
NCT07526519Phase 1Recruiting
- Sponsor
- TrueLab Biopharmaceutical
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TL-003 in ulcerative colitis (UC) (6 cohorts), sponsored by TrueLab Biopharmaceutical. Primary endpoint: Incidence and severity of Treatment Emergent Adverse Events up to 169 Days. Started Apr 2026; status: recruiting.
02
Drugs
TL-003
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07526519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07526519.